Pharmacologic management of obesity

Pediatric Blood and Cancer

Volumn 58, Issue 1, 2012, Pages 140-143

  Kushner, Robert F ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Appetite regulation; Gut peptides; Obesity; Pharmacotherapy; Weight loss

Indexed keywords

AMFEBUTAMONE; AMFEBUTAMONE PLUS NALTREXONE; AMFEPRAMONE; AMPHETAMINE; ANOREXIGENIC AGENT; EXENDIN 4; GHRELIN; GLUCAGON LIKE PEPTIDE 1; LIRAGLUTIDE; LORCASERIN; LORQUESS; METRELEPTIN; NALTREXONE; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; PRAMLINTIDE; RECOMBINANT HORMONE; RECOMBINANT HUMAN LEPTIN; SIBUTRAMINE; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG;

ABNORMAL FECES; BLOOD PRESSURE; BODY WEIGHT; CALORIC INTAKE; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM; CONSTIPATION; CONTROLLED STUDY; DEFECATION; DEFECATION URGENCY; DIZZINESS; DOPAMINERGIC SYSTEM; DRUG ABSORPTION; DRUG ACTIVITY; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; FAT INTAKE; FLATULENCE; FOOD AND DRUG ADMINISTRATION; FOOD INTAKE; GASTROINTESTINAL TRACT; GLYCEMIC CONTROL; HEADACHE; HEALTH PRACTITIONER; HEART RATE; HUMAN; INSOMNIA; LOW CALORY DIET; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; NORADRENERGIC SYSTEM; OBESITY; PALATABILITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SATIETY; SEROTONINERGIC SYSTEM; SIDE EFFECT; VALVULAR HEART DISEASE; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; HUMANS; OBESITY; WEIGHT LOSS;

EID: 81155148930     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23366     Document Type: Review

References (35)

1. National Heart, Lung, and Blood Institute (NHLBI) and National Institute for Diabetes and Digestive and Kidney Diseases (NIDDKD). Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. The evidence report. Obes Res 1998; 6(Suppl 2): 51S-210S.
2. Kordik CP, Reitz AB. Pharmacological treatment of obesity: therapeutic strategies. J Med Chem 1999; 42: 181-201.
3. Shekelle PG, Morton SC, Maglione M, et al. Pharmacological and surgical treatment of obesity. Summary evidence report/technology assessment no. 103. AHRQ publication no. 04-E028-1. Rockville, MD: Agency for Healthcare Research and Quality; July 2004.
4. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss. A systematic review. Arch Intern Med 2004; 164: 994-1003.
5. James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363: 905-917.
6. Lucas KH, Kaplan-Machlis B. Orlistat-A novel weight loss therapy. Ann Pharmacother 2001; 35: 314-328.
7. O'Meara SO, Riemsma R, Shirran L, et al. A systematic review of the clinical effectiveness of orlistat used for the management of obesity. Obes Rev 2004; 5: 51-68.
8. Padwal RS, Majumdar SR. Drug treatments for obesity: Orlistat, sibutramine, and rimonabant. Lancet 2007; 369: 71-77.
9. Rucker D, Padwal R, Li SK, et al. Long term pharmacotherapy for obesity and overweight: Updated meta-analysis. Br Med J 2007; 335: 1194-1199.
10. Beglinger C, Degen L. Gastrointestinal satiety signals in humans-Physiologic roles for GLP-1 and PYY? Physiol Behav 2006; 89: 460-464.
11. Drucker DJ, Nouck MA. The incretin system: Glucagons-like peptide-1 receptor agonist and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.
12. Neff LM, Kushner RF. Emerging role of GLP-1 receptor agonists in the treatment of obesity. Diabetes Metab Obes Targets Ther 2010; 3: 1-11.
13. Riddle MC, Drucker DJ. Emerging therapies mimicking the effects of amylin and glucagons-like peptide 1. Diabetes Care 2006; 29: 435-449.
14. Verdich C, Flint A, Gutzwiller JP, et al. A meta-analysis of the effect of glucagons-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001; 86: 4382-4389.
15. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glyemic control over 30 weeks in patients treated with meformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-1091.
16. Wynne K, Park AJ, Small CJ, et al. Subcutaneous oxyntomodulin reduced body weight in overweight and obese subjects. A double-blind, randomized, controlled trial. Diabetes 2005; 54: 2390-2395.
17. Astrup A, Rossner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: A randomized, double-blind, placebo-controlled study. Lancet 2009; 374: 1606-1616.
18. Chapam I, Parker B, Doran S, et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia 2005; 48: 838-848.
19. Chapman I, Parker B, Doran S, et al. Low-dose pramlintide reduced food intake and meal duration in healthy, normal-weight subjects. Obesity 2007; 15: 1179-1186.
20. Aronne L, Fujioka K, Aroda V, et al. Progressive reduction in body weight after treatment with amylin analog pramlintide in obese subjects: A phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab 2007; 92: 2977-2983.
21. Ravussin E, Smith SR, Mitchell JA, et al. Enhanced weight loss with pramlintide/metreleptin: An integrated neurohormonal approach to obesity pharmacotherapy. Obesity 2009; 17: 1736-1743.
22. Connelly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337: 581-588.
23. Jollis JG, Landolfo CF, Kisslo J, et al. Fenfluramine and phentermine and cardiovascular findings: Effect of treatment duration on prevalence of valve abnormalities. Circ 2000; 101: 2071-2077.
24. Gardin JM, Schumacher D, Constantine G, et al. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 2000; 283: 1703-1709.
25. Lam DD, Przydzial MJ, Ridley SH, et al. Serotonin 5-HT2c receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. Endocrinology 2008; 149: 1323-1328.
26. Smith BM, Thompson WJ, Grottick AJ. The potential use of selective 5-HT2c agonists in treating obesity. Expert Opin Investig Drugs 2006; 15: 257-266.
27. Giorgetti M, Tecott LH. Contributions of 5-HT2C receptors to multiple actions of central serotonin systems. Eur J Pharm 2004; 488: 1-9.
28. Miller KJ. Serotonin 5-ht2c receptor agonists: potential for the treatment of obesity Mol Interv 2005; 5: 282-291.
29. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight managment. N Engl J Med 2010; 363: 245-256.
30. Aronne LJ, Thornton-Jones ZD. New targets for obesity pharmacotherapy. Clin Pharm Ther 2007; 81: 748-752.
31. Grossman HC, Hadjimarkou MM, Silva RM, et al. Interrelationships between mu opiod and melanocortin receptors in mediating food intake in rats. Brain Res 2003; 991: 240-244.
32. Anderson JW, Greenway FL, Fujioka K, et al. Bupropion SR enhances weight loss: A 48-week double-blind, placebo-controlled trial. Obes Res 2002; 10: 633-641.
33. Greenway FL, Fujioka K, Pladkowski RA, et al. Effect of naltrexone plus buproprion on weight loss in overweight and obese adults (COR-1): Multicentre, randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376: 595-605.
34. Wilding J, Van Gaal L, Rissanen A, et al. A randomized double-blinds placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes 2004; 28: 1399-1410.
35. Astrup A, Caterson I, Zelissen P, et al. Topiramate: Long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res 2004; 12: 1658-1669.